INTRODUCTION AND OBJECTIVES:
A recent study published in the New England Journal of Medicine found that CHEK2 germline pathogenic mutations are associated with metastatic prostate cancer (PCa) risk. The objective of this study is to assess whether CHEK2 germline mutations differentiate risk of lethal from indolent PCa.
METHODS: A retrospective case-case study of 261 patients who died of PCa and 352 patients with localized PCa of European American descent was conducted. Germline DNA from each of the 613 subjects was sequenced for DNA repair genes and cancer-related genes through whole exome sequencing (WES) or targeted sequencing. Mutations were annotated according to the American College of Medical Genetics guidelines.
RESULTS: Among the 613 PCa patients in the study, 11 (1.79%) carried CHEK2 germline pathogenic mutations, which was significantly higher than the estimate from the general population (ExAC database: 0.61%, P<0.0001). However, the mutation carrier rate in lethal PCa patients (5/261¼1.92%) was not significantly higher than either the localized cases in our study (6/352¼1.70%, P¼1.00) or in The Cancer Genome Atlas (2/406¼0.49%, P¼0.12). Among lethal cases, CHEK2 mutation carriers and non-carriers had similar mean age of death (77.0 and 73.0 years, respectively, P¼0.72) and mean time to death (10.0 and 8.0 years, respectively, P¼0.96). In the survival analysis of the entire study, CHEK2 mutations did not predict PCa-specific survival (Figure, log-rank P¼0.86, comparing with non-carriers). In contrast, germline mutations of BRCA1/2 and ATM predicted worse PCa specific survival (all log-rank P<0.05, comparing with CHEK2 carriers and non-carriers).
CONCLUSIONS: CHEK2 germline mutations increase risk for PCa, but do not differentiate risk of lethal from indolent disease or PCaspecific survival.
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The study is partially supported by the National Key Basic Research Program Grant 973 of China (2012CB518301), the Key Project of the National Natural Science Foundation of China (81130047) However, development of resistance to these agents frequently occurs. Androgen receptor variants, particularly AR-V7, have been shown to drive resistance to abiraterone and enzalutamide. This study aimed to test whether niclosamide can overcome resistance and improve therapies by targeting androgen receptor variants.
METHODS: Resistant prostate cancer cells to enzalutamide and abiraterone were generated by continuous culturing the cells in media containing increasing doses of either enzalutamide or abiraterone. Drug screening was conducted using luciferase activity assay to determine the activity of AR-V7 after treatment with the compounds in the Prestwick Chemical Library, which contains about 1120 FDAapproved drugs. The effects of the identified inhibitors on AR-V7 activity and abiraterone/enzalutamide sensitivity were characterized in CRPC and enzalutamide/abiraterone resistant prostate cancer cells in vitro and in vivo.
RESULTS: Resistant prostate cancer cells to enzalutamide and abiraterone were generated, respectively. Both resistance cells express high levels of androgen receptor variants including AR-V7. Drug screening identified niclosamide, an anthelmintic agent approved by FDA for the treatment of tapeworm infections, as a potent AR-V7 inhibitor in prostate cancer cells. Niclosamide significantly decreased AR-V7 protein expression by protein degradation through a proteasome dependent pathway. Niclosamide also inhibited AR-V7 transcription activity and reduced the recruitment of AR-V7 to the PSA promoter. Niclosamide inhibited resistant prostate cancer cell growth in vitro and tumor growth in vivo. Furthermore, combination of niclosamide with either enzalutamide or abiraterone resulted in significantly inhibition of enzalutamide/abiraterone-resistant tumor growth. These results suggest that niclosamide enhances abiraterone/enzalutamide therapy and overcomes resistance to abiraterone/enzalutamide in castration resistant prostate cancer cells. Based on these preclinical studies, combination of niclosamide with abiraterone/enzalutamide trials are currently underway.
CONCLUSIONS: Niclosamide is a promising inhibitor of androgen receptor variants to treat advanced prostate cancer patients, especially those resistant to abiraterone or enzalutamide. Clinical trials with combination of niclosamide and abiraterone/enzalutamide are currently underway.
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